An Important Question in Prostate Cancer Treatment Answered at ESMO

Hormone therapy has been known to work in prostate cancer since the 1940s. However, until this year we had not found a satisfactory answer to the question: what is the best initial treatment for high-risk advanced prostate cancer ? Prostate cancer raised this important question: is the answer “combined new-generation hormonal therapy” or “conventional hormonal therapy together with chemotherapy”? Extensive clinical research compared them, and analyses found similar efficacy for these two treatment approaches.
This Result Was Important in Two Respects:
- First, compared with a treatment such as chemotherapy that is difficult to administer and manage for side effects, adding the new-generation hormonal treatment Abiraterone to easier-to-manage conventional hormone therapy proved as effective as chemotherapy, a development that pleased us.
- Second, after Abiraterone, a new-generation hormonal treatment, had results announced in June at 2017 ASCO, the two successful studies raised the possibility that the routine chemotherapy we offer patients might be worse than the hormone therapy combination, because we would be unable to use this treatment as a first option for a long time, as it was not yet approved in our country. The scientists conducting the study interpreted the results as meaning that because the two treatment strategies are similar in efficacy, there is no objection to preferring the available treatment option .
Study Details
STAMPEDE, a specially designed study that had previously shown the efficacy of the chemotherapy docetaxel and hormonal treatment abiraterone in prostate cancer, compared these two agents this time. In this part of the research, results from patients enrolled between 2011 and 2013, totaling 566, were analyzed and presented at ESMO 2017. Of the patients, 189 received docetaxel and 377 received abiraterone.
You may be interested in:
The study aimed to compare overall survival with these two treatment approaches, and, as noted above, no significant difference was found in survival outcomes.
For initial treatment of advanced high-risk prostate cancer, adding docetaxel chemotherapy or abiraterone to standard hormonal therapy was compared not only in survival but also in side effects, and the frequency of serious side effects was similar.
Conclusion
For a patient with advanced prostate cancer, if two treatments have similar efficacy, the one offering better quality of life and fewer side effects should be preferred; however, an accessible, approved and cheaper treatment can also be chosen with confidence.
You May Be Interested In:
Sources
esmo.org - 08 Sep 2017
Was this article helpful?
Your feedback helps us improve our content.




Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.